Introduction
After cellular uptake, nucleoside analogues often require enzymatic activation (e.g. phosphorylation) to exert biological activity. However they may also be subject to enzymatic inactivation. Therefore, the anticancer activity of purine-and pyrimidine-based antimetabolites is highly dependent on the expression of nucleoside-metabolizing enzymes in tumor cells (Galmarini et al., 2002; Parker, 2009) . The reversible phosphorolysis of purine and pyrimidine nucleosides to their respective nucleobases and sugar derivatives [(2'-deoxy)-ribose-1-phosphate] is catalyzed by nucleoside phosphorylases (NPs). In vivo, nucleoside phosphorolysis by NPs is highly favoured over nucleoside synthesis. Structural studies revealed two distinct classes of NPs: the NP-I family containing purine nucleoside phosphorylases (PNPs), uridine phosphorylases (UPs) and 5'-methylthioadenosine phosphorylases; and the NP-II family containing pyrimidine nucleoside phosphorylases (PyNPs) and thymidine phosphorylases (TPs) (Pugmire and Ealick, 2002) . Mammalian PNP (E.C. 2.4.2.1) accepts 6-oxopurines (e.g. hypoxanthine and guanine) and their nucleosides [e.g. (2'-deoxy)inosine and (2'-deoxy)guanosine] but not 6-aminopurines (e.g. adenine), whereas prokaryotic PNPs may additionally accept 6-aminopurines and their nucleosides [e.g.
(2'-deoxy)adenosine] (Bzowska et al., 2000) .
NP activity may affect the efficiency of nucleoside-based chemotherapy. Blocking TP activity has been shown to increase the anticancer activity of 5-trifluorothymidine (TFT) by preventing TP-mediated breakdown of the drug to its inactive nucleobase (5-trifluorothymine) (Temmink et al., 2007) . A phase III clinical trial to investigate the benefits of the coadministration of a TP inhibitor and TFT as a treatment modality for colorectal cancer (designated TAS-102) is in progress (Yoshino et al., 2012) . In contrast, capecitabine, an This article has not been copyedited and formatted. The final version may differ from this version.
Molecular Pharmacology Fast Forward. Published on as DOI: 10.1124 at ASPET Journals on September 8, 2017 molpharm.aspetjournals.org Downloaded from MOL #88625 5 orally-administered prodrug for the treatment of metastatic breast and colorectal cancer, requires TP activity for its conversion to the active metabolite 5-fluorouracil (5-FU) (Miwa et al., 1998; Fernández-Martos et al., 2012) . Similarly, the cytostatic activity of several adenosine analogues (e.g. 6-methylpurine-2'-deoxyriboside, 2-fluoro-2'-deoxyadenosine and 2-fluoroadenine arabinofuranoside (fludarabine)) is markedly increased after (prokaryotic) PNP-mediated phosphorolysis. Since (2'-deoxy)adenosine and its analogues are generally not accepted as substrates for mammalian PNP, suicide gene therapy introducing prokaryotic PNP at the tumor site has been investigated (Parker et al., 1997; Sorscher et al., 2012) . However, due to PNP activity of commensal bacteria in healthy tissues, toxicity often limits such treatment options. Therefore, efforts have been made to generate mutant PNPs with different substrate specificity than human and wild-type prokaryotic PNP, in order to increase the chemotherapeutic selectivity at the tumor site (Bennett et al., 2003; Ardiani et al., 2012) . It can be concluded that the expression of NPs at the tumor site may have a profound effect on the chemotherapeutic efficiency, depending on the nature and mode of action of the particular nucleoside analogue.
Apart from tumor cells, the tumor microenvironment also encompasses the surrounding normal cells (inflammatory cells, cancer-associated fibroblasts, etc.) and blood vessels. Additionally, recent research has revealed that certain prokaryotes also associate with different types of cancer. Although some prokaryotic species such as Helicobacter pylori are clearly linked with carcinogenesis, the role of bacteria in cancer is often uncertain (reviewed by Mager, 2006; Cummins and Tangney, 2013) . However, mapping the diversity of microorganisms associated with the different tissues of the human body (referred to as the microbiome) leads to new insights in several diseases (e.g. diabetes and inflammatory bowel disease) and the metabolic exchange between human tissues and microbiota was found to This article has not been copyedited and formatted. The final version may differ from this version.
Molecular Pharmacology Fast Forward. Published on as DOI: 10.1124 at ASPET Journals on September 8, 2017 molpharm.aspetjournals.org Downloaded from MOL #88625 6 affect the bioavailability of several types of drugs (e.g. acetaminophen) (reviewed by Nicholson et al., 2005; Clayton, 2009) . Using metabolic phenotypes to predict the metabolism or toxic effect of drugs has been proposed as a strategy towards a more personalized healthcare and was defined by Clayton et al. (2006) as pharmacometabonomics.
Studying the effect of bacterial colonization of tumor tissue on anticancer treatment efficiency is often limited by experimental constraints regarding the co-culturing of bacteria and mammalian tumor cells. However, the slow growth rate of mycoplasmas does allow an efficient and persistent infection of mammalian cell cultures by these bacteria. Mycoplasmas are characterized by their unusual small size and minimal genome (Razin et al., 1998) . They are a common source of cell culture contamination, and infection often remains unnoticed.
Clinically, these bacteria have been increasingly reported to preferentially colonize human tumor tissue in cancer patients (Chan et al., 1996; Kidder et al., 1998; Huang et al., 2001; Pehlivan et al., 2004 Pehlivan et al., , 2005 Yang et al., 2010; Apostolou et al., 2011; Urbanek et al., 2011; Barykova et al., 2011; Erturhan et al., 2013) . Therefore a controlled mycoplasma infection of tumor cell cultures in vitro may serve as an assay model to study the effect of prokaryotes on cancer chemotherapy. Previously we have shown that the cytostatic and antiviral activities of different thymidine and uridine analogues are dramatically decreased in mycoplasma-infected cell cultures due to the expression of a mycoplasma-encoded PyNP (Bronckaers et al., 2008; Liekens et al., 2009; Vande Voorde et al., 2012) . In the present study we report that the expression of a specific mycoplasma-encoded PNP may improve or diminish the cytostatic activity of purine nucleoside analogues depending on the nature of the drug and its mechanism of cytostatic action. A mycoplasma-encoded PNP has now been cloned, kinetically characterized for the first time and its impact on the cytostatic activity of purine nucleoside analogues investigated. This article has not been copyedited and formatted. The final version may differ from this version. 
and 6-methylpurine-2'deoxyriboside (6-MeP-dR). 8-Aminoguanosine, 2-amino-2'-deoxy-2'-fluoro-adenosine and 5,6-dichlorobenzimidazole ribofuranoside were purchased from
(radiospecificity: 7.8 Ci/mmol) was obtained from Moravek Biochemicals Inc. (Brea, CA). and NotI sites of the pGEX-5X-1 vector (Amersham Pharmacia Biotech, Uppsala, Sweden).
Cell cultures
The mycoplasma PNP was then expressed in E. coli as a GST-fusion protein according to a procedure previously described by Liekens et al. (2002) . The PNP sequence from
Mycoplasma hyorhinis (ATCC 17981) displayed two point mutations compared with M.
hyorhinis HUB-1 PNP, resulting in two mutated amino acids: E37K and R56K. SDS-PAGE revealed a GST-fusion PNP protein of ~50 kDa (25 kDa for PNP Hyor + 25 kDa for GST; data not shown).
Enzyme assays

Determination of the pH optimum
The pH optimum for PNP Hyor -mediated phosphorolysis of Adenosine (Ado), Inosine 
Kinetic assays
The enzymatic activity of PNP Hyor towards different substrates [Ado, Ino , Guo, dAdo, dIno, dGuo, 2-CdA, F-ara-A] was evaluated. The nucleoside-to-nucleobase conversion at varying concentrations of substrate ranging from 25 µM to 5 mM was studied in a reaction containing 2 or 20 nM enzyme (depending on the nucleoside conversion efficiency) incubated in PNP buffer containing 5 % DMSO (10 % DMSO for F-ara-A conversion) at 37 °C for 10 min. Kinetic parameters (K m and k cat ) were determined by means of non-linear regression analysis (using GraphPad Prism5). In the kinetic assays where the enzymatic activity of PNP Hyor was evaluated at varying concentrations of P i (100 µM to 50 mM), the nucleoside This article has not been copyedited and formatted. The final version may differ from this version. 13 substrate was kept fixed at a concentration of ∼ 10 x K m . After incubation, samples were processed and analyzed by HPLC as described above.
PNP inhibition assays
In the assays where the inhibitory effect of the PNP inhibitors Imm-H and DADMeImm-H was evaluated, different inhibitor concentrations (ranging between 1 and 1,000 nM)
were added to a reaction mixture that contained 100 µM substrate (Ado, Ino, Guo, 2-CdA or 2-F-ara-A) in PNP buffer containing 2 mM P i (reaction mixture for human PNP) or 200 mM P i (reaction mixture for PNP Hyor ). Next, the reaction mixture was exposed to human PNP (3 nM) or PNP Hyor (20 nM) and after 15 min incubation at 37 °C, the substrate degradation was determined by HPLC analysis as described above.
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Results
Mycoplasma PNP alters the cytostatic activity of purine nucleoside analogues
Human breast carcinoma MCF-7 cell cultures were infected with Mycoplasma hyorhinis (designated MCF-7.Hyor) and used to study the effect of the mycoplasma infection on the antiproliferative activity of various anticancer purine nucleoside and nucleobase analogues.
Tumor cell cultures were exposed to varying concentrations of the anti-neoplastic purine nucleoside analogue 2-chloro-2'-deoxyadenosine (2-CdA; cladribine) [within the range of the actual levels reached in leukaemia cells of cancer patients (100-400 nM plasma levels at the end of drug injection period; 40-50 µM intracellular levels) (Liliemark et al., 1997) ]. As shown in Table 1 , the cytostatic activity of 2-CdA (used for the treatment of various lymphoproliferative diseases), was decreased by 10-fold in MCF-7.Hyor tumor cell cultures (IC 50 = 13 µM) compared with mycoplasma-free control MCF-7 tumor cells (IC 50 = 1.3 µM).
Using an MTS colorimetric assay, the 50% cytotoxic concentration (CC 50 ) of 2CdA was determined to be > 50 µM and 27 ± 0.07 µM in MCF-7 and MCF-7.Hyor cells, respectively (data not shown). Pretreatment of MCF-7.Hyor tumor cell cultures with tetracycline at 1 µg/mL for 6 days efficiently eliminated the mycoplasma-infection [undetectable by the MycoAlert TM mycoplasma detection kit (Lonza)] and fully restored the cytostatic activity of 2-CdA (IC 50 = 0.70 ± 0.11 µM) (data not shown). Also, the co-administration of DADMe-
Immucillin-H (DADMe-Imm-H; 10 µM), a specific and potent PNP inhibitor (Evans et al., 2003) , rescued the antiproliferative activity of 2-CdA in MCF-7.Hyor cells (IC 50 = 0.69 µM)
but did not affect its activity in non-infected MCF-7 control tumor cell cultures (IC 50 = 1.1 µM) (Table 1) . Thus, these results suggest that a mycoplasma-encoded PNP, specifically expressed in MCF-7.Hyor cell cultures, efficiently catalyzes the phosphorolysis of 2-CdA This article has not been copyedited and formatted. The final version may differ from this version. resulting in the release of the free base 2-chloroadenine (2-CAde) which has a much lower cytostatic potential. As displayed in Table 2 , 2-CAde indeed exerts a ~10-fold lower cytostatic activity compared with 2-CdA in non-infected control MCF-7 cell cultures (IC 50 = 11 µM versus 1.3 µM, respectively). The cytostatic activity of 2-CAde is neither affected by mycoplasma infection nor by co-administration of the potent PNP inhibitor DADMe-Imm-H (Table 2) .
M. hyorhinis infected and non-infected tumor cell cultures were also exposed to varying concentrations of the adenosine analogue 2-fluoroadenine-arabinofuranoside (F-ara-A; fludarabine) [within the range of the actual levels reached in leukaemia cells of cancer patients (~3 µM plasma levels at the end of the drug infusion; 20-60 µM intracellular levels) (Gandhi and Plunkett, 2002) ]. In contrast to 2-CdA, the antiproliferative activity of F-ara-A was increased ~130-fold in MCF-7.Hyor cell cultures (IC 50 = 0.30 µM) compared with noninfected MCF-7 tumor cell cultures (IC 50 = 39 µM) ( Table 1 ). The CC 50 of F-ara-A was determined using an MTS colorimetric assay and showed to be > 50 µM and 4.8 ± 0.7 µM in MCF-7 and MCF-7.Hyor cells, respectively (data not shown). F-ara-A is administered to patients as the 5'-monophosphate for the treatment of haematological malignancies (Galmarini et al., 2002) . The increased cytostatic activity of F-ara-A in MCF-7.Hyor cell cultures could again be reduced by (i) elimination of the mycoplasmas from the cell cultures using tetracycline (resulting in an IC 50 of 27 ± 16 µM) (data not shown) or (ii) the coadministration of DADMe-Immucillin-H (resulting in an IC 50 of 22 µM) ( Table 1) . In contrast to 2-chloroadenine, 2-fluoroadenine (nucleobase of fludarabine; 2-FAde) proved ~ 280-fold more cytostatic (IC 50 = 0.14 µM) compared with its nucleoside in non-infected MCF-7 tumor cell cultures (Table 2) . These findings strongly suggest that a mycoplasma PNP-mediated release of the highly cytostatic 2-FAde base from the parent F-ara-A is responsible for its increased antiproliferative activity in mycoplasma-infected tumor cell cultures. Also a ~15-This article has not been copyedited and formatted. The final version may differ from this version. (Table 1) .
Similar to fludarabine, the cytostatic activity of 6-methylpurine-2'deoxyriboside (6-MeP-dR) was increased ~45-fold in MCF-7.Hyor tumor cell cultures compared with noninfected MCF-7 tumor cell cultures presumably due to the release of the highly cytostatic 6-methylpurine base (6-MeP) ( Tables 1 & 2) . Co-administration of DADMe-Imm-H annihilated the increased cytostatic activity of 6-MeP-dR in the mycoplasma-infected tumor cell cultures (Table 1 ). As shown in Table 2 , the cytostatic activity of 6-methylpurine was unaffected by (i) mycoplasma infection and (ii) co-administration of DADMe-Imm-H.
A slightly (3-fold) decreased cytostatic activity of 6-mercaptopurine riboside and 6-thioguanosine was observed in MCF-7.Hyor cell cultures (IC 50 = 2.2 µM and IC 50 = 1.3 µM, respectively) compared with non-infected cell cultures (IC 50 = 0.75 µM and IC 50 = 0.44 µM, respectively). Co-administration of DADMe-Imm-H dramatically decreased the cytostatic activity of both molecules in the non-infected MCF-7 tumor cells, suggesting that human PNP-directed metabolism (and thus, free purine base formation) is required for these molecules to exert their biological activity. Co-administration of DADMe-Imm-H also markedly decreased the cytostatic activity of 6-thioguanosine in MCF-7.Hyor cells but this effect was not observed for 6-mercaptopurine riboside. As displayed in Table 2 , 6-mercaptopurine and 6-thioguanine showed a cytostatic activity comparable to their riboside counterparts and were unaffected by mycoplasma infection. The antiproliferative activity of 6-mercaptopurine was somewhat compromised by the co-administration of DADMe-Imm-H in MCF-7 cell cultures (∼ 6-fold) but not in MCF-7.Hyor cell cultures. In contrast, the cytostatic activity of 6-thioguanine was not affected by PNP inhibition in both non-infected and mycoplasma-infected tumor cell cultures.
This article has not been copyedited and formatted. The final version may differ from this version. The activities of other nucleoside analogues (i.e. 8-aminoguanosine, 5,6-dichlorobenzimidazole ribofuranoside, 2-amino-2'-deoxy-2'-fluoroadenosine and adenine arabinofuranoside) were also evaluated but were not affected by mycoplasma infection nor by DADMe-Imm-H administration (Table 1) .
Metabolism of cladribine in mycoplasma-infected and uninfected cell cultures
The metabolism of 2-CdA to its 5'-triphosphate metabolite and subsequent incorporation in nucleic acids (DNA and RNA) was evaluated (Fig. 1) . Since 2-CdA is phosphorylated by 2'-deoxycytidine kinase (dCK), we compared the metabolic conversion of system ATP and dATP eluted at nearly identical retention times, we assumed that the 5'-triphosphate of 2-CdA and 2-CAdo also virtually co-eluted on the anion-exchange column, and thus, we could not discriminate between both metabolites based on their retention times.
Stability of cladribine in the medium of mycoplasma-infected and uninfected cell cultures
Radiolabeled [8-³H]-2-CdA (2 µCi) was exposed to the cell-free medium of three day- with virtually complete phosphorolysis being observed after 6 h and 1 h incubation, respectively ( Fig. 2 A,B) . In contrast, no degradation of [8-³H]-2-CdA could be observed when exposing the drug to the cell-free medium of uninfected MCF-7 or CEM/0 cell cultures ( Fig. 2 A,B) . Since the co-administration of Imm-H to the cell-free medium of CEM.Hyor cell cultures could markedly prevent the phosphorolysis of cladribine (data not shown), PNP activity is likely responsible for the efficient cladribine breakdown in mycoplasma-infected cells.
Substrate selectivity and kinetic properties of PNP Hyor
Due to the strong evidence that a mycoplasma-encoded PNP is responsible for the marked changes in cytostatic activity of several purine nucleoside analogues, including cladribine and fludarabine, we decided to clone and express the annotated PNP gene in the genome of M. hyorhinis HUB-1. The obtained enzyme was designated as PNP Hyor and found to catalyse not only phosphorolysis of inosine (Ino) and guanosine (Guo) but also adenosine This article has not been copyedited and formatted. The final version may differ from this version. (Ado). All three purine nucleosides were found to be optimally phosphorolysed at slightly acidic conditions (pH = 6 -6.5) (Fig. 3) .
By exposing different purine nucleosides and nucleoside analogues to PNP Hyor and human PNP in the presence of P i (inorganic phosphate) the substrate selectivity of both enzymes could be determined and compared site-by-site (Table 3 ). An enzyme-catalyzed time-dependent conversion of (2'-deoxy)Ino and (2'-deoxy)Guo to their respective nucleobases (hypoxanthine and guanine) and phosphorylated sugars (2-deoxyribose-1-phosphate and ribose-1-phosphate) could be demonstrated for PNP Hyor and human PNP.
Phosphorolysis of (2'-deoxy)Ado was observed for PNP Hyor only and not for human PNP. In contrast, xanthosine was found to be a substrate for human PNP but not for the prokaryotic PNP Hyor .
Using non-linear regression analysis the kinetic parameters (K m and k cat ) of PNP Hyorcatalyzed nucleoside conversion were determined for different substrates and the phosphorolytic capacity (k cat /K m ) was calculated as an estimate for the catalytic efficiency of the enzyme (Table 4) Comparable catalytic efficiencies of PNP Hyor with regard to inorganic phosphate were found when varying P i concentrations were used in the presence of saturating concentrations of the different co-substrates (Ado, Ino, Guo, dAdo or dGuo) ( Next, several purine-based nucleoside analogues with reported cytostatic or antiviral activity were evaluated as potential substrates for PNP Hyor and human PNP (Table 3) In contrast, 6-mercaptopurine-riboside, 6-thioguanosine, 8-aminoguanosine [a wellknown PNP inhibitor (Kazmers et al., 1981) ] and the RNA synthesis inhibitor 5,6-dichlorobenzimidazole ribofuranoside (Chodosh et al, 1989) , were found to be substrates for both human PNP and PNP Hyor . PNP Hyor -catalyzed phosphorolysis of 2-amino-2'-deoxy-2'fluoroadenosine and the antiherpetic adenine-arabinofuranoside (ara-A; vidarabine; PavanLangston and Buchanan, 1976) (a very poor substrate) was observed but both compounds
were not accepted as substrates by human PNP.
As displayed in Table 3 , the following relevant purine nucleoside analogues were tested and found to be no substrate for PNP Hyor or human PNP: clofarabine, used in the treatment of relapsed or refractory lymphoblastic leukaemia in pediatric patients (Hijiya et al., 2012) ; 7-deaza-adenosine (Tubercidin), an adenosine analogue with cytotoxic (Acs et al., This article has not been copyedited and formatted. The final version may differ from this version. (Acs et al., 1964) and anti-trypanosomal (Drew et al., 2003) properties; 7-deaza-2'-deoxyadenosine, the lesser cytostatic 2'-deoxy-derivative of Tubercidin (Acs et al., 1964) ; and the antiviral compound 3-deaza-adenosine (Gordon et al., 2003) .
Inhibitor studies
To explain the restoring effect of a PNP inhibitor on the compromised cytostatic activity of the purine nucleoside analogues in the mycoplasma-infected tumor cell cultures, we examined the susceptibility of PNP Hyor to two well-studied transition state analogue inhibitors of PNP: Immucillin-H (Imm-H) and DADMe-Imm-H. These compounds are studied in phase II clinical for their use in the treatment of T-cell malignancies and gout, respectively (Balakrishnan et al., 2010; Schramm, 2013) . We compared the capacity of the inhibitors to block the catalytic activity of PNP Hyor and human PNP. As shown in Table 5 , both compounds efficiently inhibited human PNP-catalyzed Ino and Guo phosphorolysis in the low nanomolar range. PNP Hyor was also found to be highly susceptible to inhibition by both compounds. Imm-H efficiently blocked PNP Hyor -catalyzed Ino and Guo phosphorolysis (IC 50 = 69 nM and 76 nM, respectively). In addition, the PNP Hyor -catalysed phoshorolysis of Ado, which is not a substrate for human PNP, was also efficiently prevented (IC 50 = 90 nM).
The PNP Hyor -mediated phosphorolysis of cladribine and fludarabine, both not recognized as substrate for human PNP, was also inhibited by Imm-H (IC 50 = 405 nM and 60 nM, respectively). DADMe-Imm-H proved to be more efficient than Imm-H in inhibiting PNP Hyorcatalyzed breakdown of Ado, Ino and Guo (IC 50 = 18, 8.4 nM and 24 nM, respectively).
DADMe-Imm-H also efficiently inhibited the PNP Hyor -mediated breakdown of cladribine and fludarabine at low nanomolar concentrations (IC 50 = 45 nM and 40 nM, respectively).
Discussion
Mycoplasmas are common cell culture contaminants, causing infections that often remain unnoticed. Previously, we described the inactivation of several cytostatic/antiviral pyrimidine nucleoside analogues in mycoplasma-infected tumor cell cultures due to the expression of a broad-spectrum mycoplasma-encoded pyrimidine nucleoside phosphorylase (PyNP) (Bronckaers et al., 2008; Vande Voorde et al., 2012) . We now show that the presence of mycoplasmas in tumor cell cultures also severely affects the antiproliferative effect of several purine-based nucleoside analogues provided that they are a substrate for mycoplasma PNP but not for human PNP. Depending on the properties of the purine nucleobase, mycoplasma infection of the tumor cell cultures resulted in a significantly increased or decreased cytostatic activity of these drugs, which could be restored by (i) suppression/elimination of the mycoplasmas by antibiotics or (ii) administration of DADMeImm-H, a potent and selective PNP inhibitor. These observations support the view that PNP Hyor plays an instrumental role in the altered cytostatic potential of a variety of purine nucleoside analogues. Since mycoplasmas (Chan et al., 1996; Kidder et al., 1998; Huang et al., 2001; Pehlivan et al., 2004 Pehlivan et al., , 2005 Yang et al., 2010; Apostolou et al., 2011; Urbanek et al., 2011; Barykova et al., 2011; Erturhan et al., 2013) and other prokaryotes (reviewed by Mager, 2006; Cummins and Tangney, 2013) Whereas mammalian PNP did not catalyze the conversion of (2'-deoxy)adenosine [(d)Ado] to adenine, PNP Hyor was found to accept not only the (deoxy)nucleoside derivatives of 6-oxopurines (hypoxanthine and guanine) but also of 6-aminopurines (adenine). Based on our kinetic studies, it could even be concluded that Ado is the preferred substrate of PNP Hyor .
Phosphorolysis proceeded optimally under slightly acidic conditions as has also been reported before for other prokaryotic and mammalian PNPs (Bzowska et al., 2000) . We found that, alike human PNP, PNP Hyor was efficiently inhibited by the well-known PNP transition state inhibitors Imm-H and DADMe-Imm-H.
We could demonstrate a ~10-fold decreased cytostatic activity of the anti-neoplastic purine nucleoside analogue cladribine (2-CdA) in mycoplasma-infected tumor cell cultures compared with uninfected control cultures. This drug is used for the treatment of various lymphoproliferative diseases and cannot be catabolyzed by human PNP (Bzowska and Kazimierczuk, 1995; our observations) . After cellular uptake, 2-CdA is phosphorylated by deoxycytidine kinase (dCK; EC 2.7.1.74) to 2-chloro-2'-deoxy-AMP and then further converted into 2-chloro-2'-deoxy-ADP and 2-chloro-2'-deoxy-ATP (Beutler, 1992) . The latter is a good substrate for DNA polymerases, competes with intracellular dATP for incorporation in the cellular DNA and ultimately induces apoptosis. Furthermore, a selfpotentiating effect of cladribine occurs due to inhibition of ribonucleotide reductase by 2-chloro-2'-deoxy-ATP, thereby depleting intracellular dNTP pools (Beutler, 1992; Parker, 2009 ). As a result, 2-chloro-2'-deoxy-ATP incorporation in cellular DNA is favoured due to the lower levels of the natural substrate dATP. Using the recombinant enzyme , we here show that 2-CdA is indeed an excellent substrate for PNP Hyor -catalyzed phosphorolysis, resulting in the release of the free nucleobase 2-chloro-adenine (2-CAde), which has a lower cytostatic This article has not been copyedited and formatted. The final version may differ from this version. (Bontemps et al., 2000) . Evidence for the formation of 2-chloro-2'-deoxy-ATP in uninfected control cells versus 2-chloro-ribo-ATP in mycoplasma-infected cells was provided by studying the metabolism of [8-³H]-2-CdA in wild-type and dCK-deficient CEM cell cultures in the presence or absence of mycoplasmas.
Indeed, incorporated radiolabel derived from [8-and Carson (1982) . In contrast to 2-CAde (the free base of cladribine), 2-FAde and 6-MeP are highly toxic after APRT-mediated intracellular metabolism (Parker et al., 1998) . F-ara-A, 2-fluoro-2'-deoxyadenosine and 6-MeP-dR were confirmed to be no substrate for human PNP and therefore display an increased cytostatic activity in mycoplasma-infected tumor cell cultures compared with non-infected cell cultures. Thus, relatively non-toxic adenosine analogues carrying a toxic base component may gain therapeutic antitumor selectivity when used to treat tumors that are associated with prokaryotes such as mycoplasmas showing efficient adenosine phosphorylase activity.
The introduction of prokaryotic (E. coli) PNP into human tumors has been explored as a selective antitumor suicide gene therapy approach (Zhang et al., 2005) . Low level expression of E. coli PNP (< 1 % of transfected tumor cells) was shown to lead to pronounced bystander killing of non-transfected tumor cells due to diffusion of 6-MeP, released from 6-MeP-dR, to adjacent tissue. A marked anticancer activity has been observed using this approach in a variety of tumors (reviewed by Ardiani et al., 2012) . In this respect we believe that mycoplasma PNPs should be added to the suicide gene armamentarium to be considered as potential gene constructs useful for specific cancer gene therapy. In search of an ideal PNP/prodrug combination, studies have also explored the possibility to generate rationally engineered prokaryotic PNPs that display a higher affinity for the newly-designed non-toxic purine-based analogues. Parker et al. (2005) This article has not been copyedited and formatted. The final version may differ from this version. In non-infected cell cultures, 2-CdA is taken up and converted by dCK and AMP kinase/NDP kinase to its 5'-triphosphate prior to incorporation into DNA. In mycoplasma-infected cell cultures, a substantial amount of 2-CdA is already converted by PNP Hyor to its free base 2-CAde prior to uptake. Once inside the cell, APRT can anabolize 2-CAde to 2-CAMP which is further converted by nucleoside kinases to its 5'-triphosphate prior to incorporation into RNA.
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